BAZ2A

Across TCGA pan-cancer cohorts, BAZ2A mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated BAZ2A data layer compared with 24 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher BAZ2A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated BAZ2A expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

CCRCC, HNSC, and COAD are the cancer types where BAZ2A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.705	1.000	<.001	76	view →
HNSC	OS	Quartile	III,IV	0.498	0.761	.001	11	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →
LUAD	OS	Median	All	0.899	0.984	.018	5	view →
PDAC	DFS	Tertile	III,IV	0.884	0.409	.026	3	view →
UCEC	DFS	Median	All	1.000	0.936	.021	2	view →
LSCC	DFS	Quartile	All	0.894	0.633	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

BAZ2A–CCRCC (DFS)

Open the CCRCC breakdown →